Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dimenhydrinate
Drug ID BADD_D00676
Description Dimehydrinate was first described in the literature in 1949,[A233120] and patented in 1950.[L32995] Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery.[A233130] Dimenhydrinate, also known as B-dimethylaminoethyl benzohydrol ether 8-chlorotheophyllinate, is indicated to prevent nausea, vomiting, and dizziness caused by motion sickness.[L32980,L32985,L32995] Dimenhydrinate is a combination of [Diphenhydramine] and [8-chlorotheophylline] in a salt form, with 53%-55.5% dried diphenhydramine, and 44%-47% died 8-chlorotheophylline.[L32985] The antiemetic properties of dimenhydrinate are primarily thought to be produced by diphenhydramine's antagonism of H1 histamine receptors in the vestibular system[A1540] while the excitatory effects are thought to be produced by 8-chlorotheophylline's adenosine receptor blockade.[A33889] When used in large doses, dimenhydrinate has been shown to cause a "high" characterized by hallucinations, excitement, incoordination, and disorientation.[A1539] Dimenhydrinate was granted FDA approval on 31 May 1972.[L32975]
Indications and Usage Dimenhydrinate is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness.[L32980,L32985]
Marketing Status approved
ATC Code R06AA11
DrugBank ID DB00985
KEGG ID D00520
MeSH ID D004111
PubChem ID 10660
TTD Drug ID D0U8UV
NDC Product Code 10237-940; 63323-366; 70677-0022; 0904-6772; 29485-1216; 29485-6925; 63029-901; 63868-034; 12711-4675; 10237-941; 11673-198; 46122-536; 52904-962; 63029-910; 0363-1980; 10267-1006; 63029-902; 49873-802; 50844-199; 63941-198; 67751-170; 10267-4186; 49452-2615; 55745-0002; 11822-0198; 36800-930; 0363-0198; 66715-9809; 70000-0404; 70677-1087; 62011-0341; 67091-118; 0904-2051; 10267-4215; 10237-942; 49035-981; 69842-206; 29485-8048; 50804-198
UNII JB937PER5C
Synonyms Dimenhydrinate | Diphenhydramine Theoclate | Theoclate, Diphenhydramine | Wehamine | Aviomarin | Biodramina | Calm-X | Calm X | Cinfamar | Contramareo | Dimen Heumann | Heumann, Dimen | Dimen Lichtenstein | Lichtenstein, Dimen | Dimetabs | Dinate | DMH | Dramanate | Gravol | Marmine | Motion-Aid | Motion Aid | Nausicalm | Reisegold | Reisetabletten Lünopharm | Lünopharm, Reisetabletten | Reisetabletten Stada | Stada, Reisetabletten | Reisetabletten-ratiopharm | Reisetabletten ratiopharm | Rodovan | RubieMen | Superpep | Travel Well | TripTone | Vertigo-Vomex | Vertigo Vomex | Vomex A | Vomacur | Vomisin | Dramamine | Apo-Dimenhydrinate | Apo Dimenhydrinate
Chemical Information
Molecular Formula C17H21NO.C7H7ClN4O2
CAS Registry Number 523-87-5
SMILES CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Intestinal obstruction07.13.01.002--Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Loss of consciousness17.02.04.004--Not Available
Malaise08.01.01.003--
Memory impairment19.20.01.003; 17.03.02.003--
Muscle spasms15.05.03.004--
Muscle spasticity17.05.03.007; 15.05.04.011--
Muscle twitching15.05.03.005--Not Available
Mydriasis06.05.03.004; 17.02.11.003--Not Available
Nasal dryness22.04.03.002--Not Available
Nausea07.01.07.001--
Nephrolithiasis20.04.01.002--
Nervousness19.06.02.003--Not Available
Nightmare19.02.03.003--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Pallor24.03.04.001; 23.03.03.031; 08.01.03.032--Not Available
Palpitations02.11.04.012--
Paraesthesia23.03.03.094; 17.02.06.005--
Phlebitis24.12.03.004; 12.02.01.002--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rash erythematous23.03.13.029--Not Available
Restlessness19.11.02.002; 17.02.05.021--
Retching07.01.07.002--Not Available
Seizure17.12.03.001--
Somnolence19.02.05.003; 17.02.04.006--
Stupor19.02.05.004; 17.02.04.007--Not Available
Suicide attempt19.12.01.004--
Swelling face08.01.03.100; 10.01.05.018; 23.04.01.018--Not Available
Tachycardia02.03.02.007--Not Available
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages